Post by Promega Corporation

Daraxonrasib just rewrote what's possible for patients with metastatic pancreatic cancer. The Phase 3 result was striking, but the story behind it goes back further than one clinical trial. RAS spent decades resisting every attempt to drug it. Each time the field found a new approach, the same question had to be answered: does this actually work inside a living cell? Here's the measurement story behind how that question got answered, from the first KRAS inhibitors through daraxonrasib. https://ow.ly/LKfo50ZgZLR